Marcus Holt
Covers the next-generation molecules — retatrutide, survodutide, and anything with three or more receptor targets in the same injection.
- Bylines on file
- 97
- Filing since
- January 2022
- On the masthead
- 4 years
- Filed from
- Chicago, Illinois
- Desks
- Tirzepatide desk (lead)Peptides & Beyond (senior contributor)
- Pronouns
- he / him
Marcus writes about pharmacology from the perspective of a chemist who can read a protocol and a journalist who can read a room. He was at C&EN for four years before joining Wellness Wire in 2022.
He has spent the last eighteen months on the dual- and triple-agonist pipeline, and is currently finishing a book on the failed obesity drugs of the 1990s and what their failure taught us about the ones that worked.
If you want to know which molecule Eli Lilly is quietly running into Phase II next quarter, he is usually the last person in the newsroom to tell you, and the first one to be right when the press release drops.
Most of my beat is reading Phase II supplementary appendices at one in the morning and trying to figure out if the effect is the molecule or the crowd. — Holt, in conversation with the newsroom